Spotlight on Pulmonary/Respiratory Medicine

Credits: 0.75 CME
Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management
Aryeh Fischer, MD
Integrity Continuing Education, Inc.

Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 10, 2018
Expires: October 10, 2019
0.75 hour(s) to complete

Provided By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

Learning Objectives

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

Activity Description

ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.

Faculty

Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 10, 2018
Expires: October 10, 2019
0.75 hour(s) to complete

Provided By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

Learning Objectives

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

Activity Description

ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.

Faculty

Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pulmonary/Respiratory Medicine Presentations

0.75 CME / MOC
Vindico
Expanding Applications for Existing Therapies in Fibrotic Lung Disease

Expanding Applications for Existing Therapies in Fibrotic Lung Disease

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™ / MOC point(s)
Released: July 24, 2019
Expires: July 23, 2020
45 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Activity Chair

Amy L. Olson, MD, MSPH
Associate Professor, Department of Medicine
Medical Director, Pulmonary Physiology Unit
National Jewish Health
Denver, CO

Disclosures:
Consulting Fee: Boehringer Ingelheim, France Foundation, PILOT Program
Speakers Bureau: Boehringer Ingelheim, France Foundation, Genentech, PILOT Program


Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosures:
Consulting Fee: Bellerophon Therapeutics, Boehringer Ingelheim, Roche/Genentech, Veracyte
Contracted Research: Boehringer Ingelheim, Roche/Genentech


Steven D. Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University - Inova Fairfax Campus
Falls Church, VA

Disclosures:
Consulting Fee: Bellerophon Therapeutics, Boehringer Ingelheim, Galapagos, Promedior, Roche/Genentech
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech


Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, July 24, 2019 to July 23, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the video, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

Interstitial lung disease (ILD) describes a group of over 200 pulmonary conditions with characteristic microscopic patterns of inflammation and fibrosis. Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive fibrosing ILD with two recently approved US Food and Drug Administration (FDA) therapies that were shown to delay pulmonary decline in patients with IPF. These FDA-approved IPF therapies are currently under investigation for the treatment of other fibrotic lung diseases, including systemic sclerosis-related ILD, progressive fibrosing ILD, and usual interstitial pneumonia. In this live satellite symposium, experts in the field will provide discussion and guidance on the timely and accurate identification of patients with progressive fibrosing ILD and evaluate the expanding applications for current IPF therapies in other fibrotic lung diseases. Furthermore, the presentation of cases will provide scientific pearls for the integration of diagnostic and therapeutic algorithms into clinical practice.

Target Audience

The intended audience for this activity is pulmonologists, internists, rheumatologists, and other health care professionals involved in the treatment of patients with progressive fibrosing interstitial lung disease (PF-ILD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize appropriate tools and classification criteria to identify patients with PF-ILD.
  • Examine the common causes and burden of PF-ILD, as well as the need for improved diagnosis and treatment.
  • Assess the latest clinical advances in the management of patients with PF-ILD.
  • Adopt a multidisciplinary approach to improve the diagnosis and treatment of patients with PF-ILD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™ / MOC point(s)
Released: July 24, 2019
Expires: July 23, 2020
45 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Activity Chair

Amy L. Olson, MD, MSPH
Associate Professor, Department of Medicine
Medical Director, Pulmonary Physiology Unit
National Jewish Health
Denver, CO

Disclosures:
Consulting Fee: Boehringer Ingelheim, France Foundation, PILOT Program
Speakers Bureau: Boehringer Ingelheim, France Foundation, Genentech, PILOT Program


Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosures:
Consulting Fee: Bellerophon Therapeutics, Boehringer Ingelheim, Roche/Genentech, Veracyte
Contracted Research: Boehringer Ingelheim, Roche/Genentech


Steven D. Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University - Inova Fairfax Campus
Falls Church, VA

Disclosures:
Consulting Fee: Bellerophon Therapeutics, Boehringer Ingelheim, Galapagos, Promedior, Roche/Genentech
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech


Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, July 24, 2019 to July 23, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the video, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Overview

Interstitial lung disease (ILD) describes a group of over 200 pulmonary conditions with characteristic microscopic patterns of inflammation and fibrosis. Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive fibrosing ILD with two recently approved US Food and Drug Administration (FDA) therapies that were shown to delay pulmonary decline in patients with IPF. These FDA-approved IPF therapies are currently under investigation for the treatment of other fibrotic lung diseases, including systemic sclerosis-related ILD, progressive fibrosing ILD, and usual interstitial pneumonia. In this live satellite symposium, experts in the field will provide discussion and guidance on the timely and accurate identification of patients with progressive fibrosing ILD and evaluate the expanding applications for current IPF therapies in other fibrotic lung diseases. Furthermore, the presentation of cases will provide scientific pearls for the integration of diagnostic and therapeutic algorithms into clinical practice.

Target Audience

The intended audience for this activity is pulmonologists, internists, rheumatologists, and other health care professionals involved in the treatment of patients with progressive fibrosing interstitial lung disease (PF-ILD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize appropriate tools and classification criteria to identify patients with PF-ILD.
  • Examine the common causes and burden of PF-ILD, as well as the need for improved diagnosis and treatment.
  • Assess the latest clinical advances in the management of patients with PF-ILD.
  • Adopt a multidisciplinary approach to improve the diagnosis and treatment of patients with PF-ILD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.75 CME
Integrity Continuing Education, Inc.
Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Exploring Novel Therapies for Scleroderma-Associated ILD: An Evidence-based Approach to Diagnosis and Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 10, 2018
Expires: October 10, 2019
0.75 hour(s) to complete

Provided By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

Learning Objectives

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

Activity Description

ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.

Faculty

Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 10, 2018
Expires: October 10, 2019
0.75 hour(s) to complete

Provided By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

Learning Objectives

  • Determine the elements of a comprehensive diagnostic workup to achieve timely diagnosis of SSc-ILD and assess patient risk for disease progression
  • Tailor treatment approaches for patients with SSc-ILD based on relevant clinical trial evidence of investigational regimens
  • Outline effective strategies for improving the physician-patient dialogue and collaboration across the multidisciplinary care team to meet the needs of patients with SSc-ILD

Activity Description

ILD is universally recognized as the most serious complication of SSc and has been identified as the leading cause of mortality among patients with SSc-ILD. Despite awareness of the risk for ILD development among patients with SSc, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement.

Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of IPF, questions have been raised about their potential to similarly impact SSc-ILD progression. While it remains to be determined whether this is indeed the case, studies to address this issue are ongoing. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.

Faculty

Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences &
Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado


David Lederer, MD
Associate Professor
Department of Medicine
Associate Division Chief
Clinical & Translational Research Director
Advanced Lung Disease Program
Columbia University
New York, New York


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aryeh Fischer, MD
Consulting Fees: Boehringer Ingelheim, F Hoffman La Roche

David Lederer, MD
Consulting Fees: Roche, Veracyte
Research: Boehringer Ingelheim

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 10, 2018 through October 10, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.